Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
- PMID: 33996460
- PMCID: PMC8099504
- DOI: 10.1016/j.imr.2021.100726
Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis
Abstract
Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.
Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.
Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD -1.54 days, 95% CI [-2.15,-0.92], I 2 = 80%, n = 385, 3 trials) and cough (MD -1.22 days, 95% CI [-1.52, -0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [-1.15, -0.21], I2 = 68%, n = 140, 2 trials) and blistering (MD -0.99 days, 95% CI [-1.23, -0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD -1.13 days, 95% CI [-1.36, -0.90], I 2 = 33%, n = 688, 7 trials) and sore throat (MD -1.13 days, 95% CI [-1.40, -0.86], I 2 = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1-5 days). No serious adverse events were reported.
Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.
Keywords: Chinese herbal medicine; Randomized controlled trials; Respiratory tract infections; Shufeng Jiedu; Systematic review.
© 2021 Published by Elsevier B.V. on behalf of Korea Institute of Oriental Medicine.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures




Similar articles
-
The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.Front Med (Lausanne). 2022 Oct 13;9:1020286. doi: 10.3389/fmed.2022.1020286. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36325392 Free PMC article.
-
Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Front Pharmacol. 2022 Jul 4;13:923395. doi: 10.3389/fphar.2022.923395. eCollection 2022. Front Pharmacol. 2022. PMID: 35860018 Free PMC article.
-
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.BMC Complement Med Ther. 2020 May 24;20(1):151. doi: 10.1186/s12906-020-02924-5. BMC Complement Med Ther. 2020. PMID: 32448238 Free PMC article.
-
[Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza].Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):6216-6224. doi: 10.19540/j.cnki.cjcmm.20230804.501. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114228 Chinese.
-
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.Front Pharmacol. 2024 May 27;15:1383831. doi: 10.3389/fphar.2024.1383831. eCollection 2024. Front Pharmacol. 2024. PMID: 38863976 Free PMC article.
Cited by
-
The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.Front Med (Lausanne). 2022 Oct 13;9:1020286. doi: 10.3389/fmed.2022.1020286. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36325392 Free PMC article.
-
Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.Front Pharmacol. 2023 Sep 25;14:1221905. doi: 10.3389/fphar.2023.1221905. eCollection 2023. Front Pharmacol. 2023. PMID: 37818189 Free PMC article.
-
Efficacy and safety of herbal medicine (Binafuxi granules) for the common cold with fever: A multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.Integr Med Res. 2023 Sep;12(3):100956. doi: 10.1016/j.imr.2023.100956. Epub 2023 May 19. Integr Med Res. 2023. PMID: 37359288 Free PMC article.
-
Yuye Jinhua Qingre Tablets Attenuate Acute Pharyngitis by inhibiting the Complement Cascade and C5a/C5aR1 Axis.Chin Med. 2025 Aug 25;20(1):134. doi: 10.1186/s13020-025-01191-1. Chin Med. 2025. PMID: 40855320 Free PMC article.
-
Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Front Pharmacol. 2022 Jul 4;13:923395. doi: 10.3389/fphar.2022.923395. eCollection 2022. Front Pharmacol. 2022. PMID: 35860018 Free PMC article.
References
-
- James S.L., Abate D., Abate K.H., Abay S.M., Abbafati C., Abbasi N. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet North Am Ed. 2018;392(10159):1789–1858. - PMC - PubMed
-
- Geneva . WHO; 2020. Disease Burden and Mortality Estimates.http://www.who.int/gho/mortality_burden_disease/en/index.html website. Published 2018. Accessed June 20.
-
- Vol. 23. WHO; 2021. http://www.bmj.com/content/346/bmj.f2914 (International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)). website. Published 2019. Accessed February. - PubMed
-
- Harris A.M., Hicks L.A., Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the american college of physicians and the centers for disease control and prevention. Ann Intern Med. 2016;164(6):425–434. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources